4D pharma plc's (LON:DDD) Alex Stevenson speaks to Proactive London's Katie Pilbeam about the company's latest report which showed positive data for its phase II trial of its live biotherapeutic for irritable bowel syndrome (IBS).
He says the results provide the foundation for continued development of the first drug with the potential to treat both major subtypes of the condition, in both IBS-C and IBS-D subgroups. Stevenson discusses the timeline for Phase III which he says 'would probably take around two years' in several hundred patients.
He also updates investors on his research into oncology and asthma.
